Cardiac resynchronization therapy

Global Cardiac Bio Implant Devices Market Size and Forecast Report 2023: A $60+ Billion Industry by 2030 - Growing Attractiveness of Bio-implant Treatments Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 15, 2024
Biotechnology, Health, Cardiology, Medical Devices, Ageing, Diabetes, Obesity, Moyamoya disease, American Heart Association, Woman, Arthroscopy, Beauty, Binge drinking, Incidence, Cardiac catheterization, CRT, Angiography, Smoking, Application, Heart failure, Element, Echocardiography, ISR, USD, Cardiac resynchronization therapy, IHD, Diagnosis, Prevalence, Medical device

The "Cardiac Bio Implant Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Bio Implant Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Cardiac Bio-Implants Device Market size is estimated to be US$ 60.20 Billion by 2030.
  • The global cardiac bio-implants market changed into worth USD 34.70 Billion in 2022.
  • The growth of the Cardiac Catheterization laboratory market is primarily fueled by the increasing prevalence of cardiovascular disorders and advancements in Cardiac Catheterization lab technology.

SmartCardia names Dr. Jag Singh as a Principal Advisor

Retrieved on: 
Monday, November 13, 2023
Massachusetts General Hospital, Cardiac resynchronization therapy, Research, University of Oxford, Framingham Heart Study, Mass, Cardiac electrophysiology, Artificial intelligence, Journal, Science, Harvard Medical School, Roman, Digital health, Publication, Lead, Hospital, Medical device, Cardiology, Medicine

LAUSANNE, Switzerland, Nov. 13, 2023 /PRNewswire/ -- SmartCardia is pleased to introduce Dr. Jag Singh as their new Principal Medical Advisor.

Key Points: 
  • LAUSANNE, Switzerland, Nov. 13, 2023 /PRNewswire/ -- SmartCardia is pleased to introduce Dr. Jag Singh as their new Principal Medical Advisor.
  • Dr. Singh joins SmartCardia with over 25 years of medical experience and will lead their advisory team.
  • In this position, Dr. Singh will work with SmartCardia to optimize and innovate their digital health offerings and envision future platforms and programs.
  • "We are excited to have Dr. Jag Singh as our Principal Advisor.

Impulse Dynamics Receives Full-Body MRI-Conditional Approval for Optimizer Smart Mini System

Retrieved on: 
Monday, October 30, 2023
NYHA, FDA, MRI, Heart failure, Heart, CRT, Physician, Cardiac resynchronization therapy, Quality of life, CCM, HF, Mathematical optimization, Patient, Google Images, Medical imaging, Medical device

MARLTON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today it has received whole-body MRI-conditional approval for the Optimizer® Smart Mini system from the United States Food and Drug Administration (FDA).

Key Points: 
  • MARLTON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today it has received whole-body MRI-conditional approval for the Optimizer® Smart Mini system from the United States Food and Drug Administration (FDA).
  • The Optimizer Smart Mini system delivers the company’s proprietary CCM® therapy.
  • The approval for use with full-body MRI covers new patients adopting CCM therapy as well as existing Optimizer Smart Mini users.
  • Long‐term clinical experience with cardiac contractility modulation therapy delivered by the optimizer smart system.

Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology

Retrieved on: 
Wednesday, October 25, 2023
NYHA, American College, Food, CRT, LVEF, Cardiac resynchronization therapy, Heel, McCutcheon, ASX, Achilles, Institutional review board, Coronary sinus, Wise, Journal, Cardiology, Patient, Food and Drug Administration, Heart failure, MD, Nissan Micra, JACC, Research, Growth, QRS, FDA, IRB, Cardiac electrophysiology, Journal of the American College of Cardiology, EBR, Medtronic, Failure, Medical device, Television, Pharmaceutical industry

The positive results published in JACC are based on a 1-year follow-up of the first-in-human implantation in the US of totally leadless CRT pacing utilizing the Micra™ leadless pacing system in the right ventricle in conjunction with EBR's investigational WiSE® CRT Electrode in the left ventricle of the heart.

Key Points: 
  • The positive results published in JACC are based on a 1-year follow-up of the first-in-human implantation in the US of totally leadless CRT pacing utilizing the Micra™ leadless pacing system in the right ventricle in conjunction with EBR's investigational WiSE® CRT Electrode in the left ventricle of the heart.
  • This first use in the US of the WiSE CRT System as a first-line therapy is a future market expansion opportunity for EBR.
  • "It's great to see these positive results being published in a world-leading cardiology journal, such as The Journal of the American College of Cardiology," said John McCutcheon, President & CEO of EBR Systems.
  • "This case study highlights the potential of totally leadless CRT for patients struggling with traditional CRT, but also beyond these patient groups, the 64 million heart failure patients across the globe."

Vektor Medical Strengthens Its Medical Advisory Board with World-renowned Leaders in Electrophysiology

Retrieved on: 
Wednesday, October 11, 2023
Radiology, Health Technology, Health, Cardiology, Algorithm, ECG, Vector, Intelligence, Mass, Cardiac resynchronization therapy, Hospital, Indiana University School of Medicine, Artificial intelligence, Workflow, FDA, Harvard Medical School, Roman, Vektor, Patient, Arrhythmia, Massachusetts General Hospital, Pharmaceutical industry, Medical device, Medicine

Vektor Medical, a pioneer in arrhythmia care and developer of the only FDA-cleared non-invasive technology to accurately map arrhythmias using just 12-lead ECG data, is delighted to announce the expansion of its esteemed Medical Advisory Board.

Key Points: 
  • Vektor Medical, a pioneer in arrhythmia care and developer of the only FDA-cleared non-invasive technology to accurately map arrhythmias using just 12-lead ECG data, is delighted to announce the expansion of its esteemed Medical Advisory Board.
  • The newly expanded Medical Advisory Board, features preeminent electrophysiology leaders, including:
    "I'm very enthusiastic about vMap's potential to transform cardiac arrhythmia care.
  • I look forward to partnering with Vektor on its mission to revolutionize arrhythmia care and increasing access to safer, more personalized and affordable patient centered care across all communities and all human beings.”
    With this distinguished Medical Advisory Board, Vektor Medical is poised to further advance its impact in arrhythmia care.
  • Vektor Medical is committed to its mission to revolutionize cardiac arrhythmia care, and the addition of these prominent experts to its Medical Advisory Board represents a significant step towards realizing that vision.

Runway Growth Finance Corp. Provides Second Quarter 2023 Portfolio Update

Retrieved on: 
Tuesday, July 11, 2023
Communication, Investment, Private law, IO, Internet of things, ASX, Cardiac resynchronization therapy, Internet, Partial, Mustang Bio, AI, Completion, EBR, INRIX, Software, Airline, Financial services, Security (finance), Bank, Elevate

WOODSIDE, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the second quarter ended June 30, 2023.

Key Points: 
  • WOODSIDE, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the second quarter ended June 30, 2023.
  • Runway Growth is poised to capitalize on select opportunities in the second half of 2023.”
    In the second quarter of 2023, Runway Growth funded four new investments in existing portfolio companies.
  • During the second quarter ended June 30, 2023, Runway Growth experienced four prepayments totaling $88.7 million and scheduled principal amortization of $2.8 million.
  • As of June 30, 2023, the Runway Growth portfolio included 33 debt investments to 31 portfolio companies and 58 equity investments in 43 portfolio companies, including 25 portfolio companies where Runway Growth holds both a debt and equity investment.

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

Retrieved on: 
Thursday, June 29, 2023
Carcinoma, Progression-free survival, Survival, Lung cancer, Cancer, Cardiac resynchronization therapy, Prognosis, SOC, NSCLC, Trial of the century, Global Research, SCLC, BTLA, Junshi, SSE, Development, HIV disease progression rates, Patient, Standard of care, Mortality, Hospital, MOS, Chemoradiotherapy, CRT, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Safety, Small-cell carcinoma, Pharmaceutical industry

According to GLOBOCAN 2020, lung cancer is a form of malignant tumor with the highest incidence rate and mortality in China.

Key Points: 
  • According to GLOBOCAN 2020, lung cancer is a form of malignant tumor with the highest incidence rate and mortality in China.
  • Lung cancer can be broadly categorized into non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”), based on cell type.
  • Specifically, small cell lung cancer is the most invasive subtype of lung cancer, accounting for about 15%-20% of all lung cancer cases with characteristics such as rapid progression, early metastasis, and poor prognosis.
  • Small cell lung cancer includes limited-stage small cell lung cancer (“LS-SCLC”) and extensive-stage small cell lung cancer, and LS-SCLC accounts for about one-third of all small cell lung cancer cases.

LATE-BREAKING TRIAL PRESENTED AT HRS SHOWS MEASURABLE DIFFERENCE IN OUTCOMES BETWEEN PATIENTS BY SEX

Retrieved on: 
Friday, June 9, 2023
Arrhythmia, Heart Rhythm Society, Male, NICM, University, Subcutaneous Implantable Defibrillator (S-ICD), Life, CRT-D, Woman, Research, Tachycardia, Doctor of Philosophy, Physician, Cardiomyopathy, Death, Cardiac resynchronization therapy, Conference, Female, Birth control, Medical device, Nursing, MD, Patient

LAKE OSWEGO, Ore., June 9, 2023 /PRNewswire/ -- Data presented at Heart Rhythm Society's 2023 Conference show a measurable difference in outcomes between male and female patients when looking at one-year ventricular tachyarrhythmia or death rates in patients with non-ischemic cardiomyopathy (NICM) with an ICD or CRT-D.

Key Points: 
  • Historically, women have been underrepresented in studies of patients with implantable cardiovascular medical devices, making it impossible to draw measurable conclusions of differences between sex.
  • "The BIO-LIBRA model will lead the way women are enrolled in medical device studies in the next decades," says Dr. Valentina Kutyifa.
  • "A large, properly powered study was much needed to better understand sex-specific outcomes in non-ischemic cardiomyopathy patients, and the BIO-LIBRA study sheds new light on the intricate interconnected relationship between sex and race on outcomes."
  • Contemporary Outcomes of Non-Ischemic Cardiomyopathy Patients with an Implanted Defibrillator or Cardiac Resynchronization Therapy (BIO-LIBRA).

SentiAR Announces Close of $8.5 million Series B Financing

Retrieved on: 
Tuesday, April 11, 2023
Heart, Augmented reality, Anatomy, 3D, MBA, Doctor of Philosophy, Harvard Medical School, MD, Patient, Physician, AR, Cardiac resynchronization therapy, Medical imaging, Medicine

ST. LOUIS, April 11, 2023 /PRNewswire/ -- SentiAR, Inc. a St. Louis, Missouri based pioneer in using Augmented Reality (AR) visualization technology for medical procedures, has closed an $8.5 million Series B financing.  The financing was led by cultivate (MD) Ventures and joined by MedVenture Partners alongside several insider investors, including TechWald Holding, VCapital, QRM Capital, and Harmonix Fund. The funding will allow the company to launch additional partnerships and wider clinical deployments.   

Key Points: 
  • ST. LOUIS, April 11, 2023 /PRNewswire/ -- SentiAR, Inc. a St. Louis, Missouri based pioneer in using Augmented Reality (AR) visualization technology for medical procedures, has closed an $8.5 million Series B financing.
  • The financing was led by cultivate (MD) Ventures and joined by MedVenture Partners alongside several insider investors, including TechWald Holding, VCapital, QRM Capital, and Harmonix Fund.
  • The company's innovative first product, CommandEP™, integrates existing imaging systems to create a real time 3D holographic interface.
  • CommandEP is the first application of its kind in the world and SentiAR anticipates completion of new clinical studies in the second half of this year.

Presidio Medical™ Announces Executive Appointment

Retrieved on: 
Tuesday, March 21, 2023
Science, Cardiology, Other Science, Health, Medical Devices, Health Technology, Clinical Trials, Other Health, R&D, ULF, DME, Presidio, SJM, Program management, Cardiac resynchronization therapy, Organization, Development, Senior, Durable medical equipment, Acquisition, Divisional patent application, Supply chain, Patient, Ultra, Heart failure, Growth, Chronic pain, St. Jude Medical, Medical device, Management, Operation

Presidio Medical, Inc., a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, announced that Scott Salys joined the Executive Team as Chief Research & Development and Operations Officer.

Key Points: 
  • Presidio Medical, Inc., a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, announced that Scott Salys joined the Executive Team as Chief Research & Development and Operations Officer.
  • Mr. Salys joins Presidio from Abbott where he was most recently the Divisional Vice President of R&D of the Heart Failure business.
  • “We are thrilled to have someone with Scott’s breadth of experience across Operations, Supply Chain, and R&D join the Presidio team.
  • “I am excited to join this incredibly talented team and lead Presidio Medical through the next stage of clinical and product development.